28 May 2019
Visiongain has launched a new pharma report Checkpoint Inhibitors for Anti-Cancer Treatment Market Report: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs.
Checkpoint inhibitors have changed the landscape of melanoma treatment in the last few years and advanced it in ways that could not have been possible before. The response rates achieved and survival rates are so much higher than any seen before and metastatic melanoma patients are living much longer. The global checkpoint inhibitor for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.
The lead analyst of the report commented "One opportunity for driving growth in the checkpoint inhibitor market is the development of companion diagnostic tests. These tests would be indispensable as they would allow treatment to be given only to those patients who would derive the most benefit from it and not add to the cost burden by eliminating patients who would gain no advantage from using this treatment or would be susceptible to severe side effects such as autoimmune-related effects."
Leading companies featured in the report include AstraZeneca, Plc, Bristol-Myers Squibb Co., Celldex Therapeutics, Inc., Incyte Corporation, Merck & Co., Inc, Novartis, Pfizer, Roche and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.